Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15123792 | 1.00 | CYP2E1 (0.66) | CYP2E1NR1I2EPHX2ALDH1A1KDM4E | |
| SCHEMBL15130716 | 0.91 | CYP2E1 (0.79) | CYP2E1NR1I2EPHX2ALDH1A1GLA | |
| SCHEMBL319216 | 0.91 | CYP2E1 (0.64) | CYP2E1NR1I2EPHX2ALDH1A1KDM4E | |
| SCHEMBL10265151 | 0.91 | CYP2E1 (0.64) | CYP2E1NR1I2EPHX2ALDH1A1KDM4E | |
| SCHEMBL15124146 | 0.90 | CYP2E1 (0.53) | CYP2E1NR1I2ALDH1A1 | |
| SCHEMBL10265483 | 0.90 | CYP2E1 (0.53) | CYP2E1NR1I2ALDH1A1 | |
| SCHEMBL319040 | 0.89 | CYP2E1 (0.67) | CYP2E1NR1I2EPHX2ALDH1A1GLA | |
| SCHEMBL319041 | 0.89 | CYP2E1 (0.67) | CYP2E1NR1I2EPHX2ALDH1A1GLA | |
| SCHEMBL10265040 | 0.89 | CYP2E1 (0.67) | CYP2E1NR1I2EPHX2ALDH1A1KDM4E | |
| SCHEMBL15123904 | 0.89 | CYP2E1 (0.67) | CYP2E1NR1I2EPHX2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SLC10A1, ACE, CEL | CYP2E1 1027/4885NR1I2 1500/4885EPHX2 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.